(Q36940606)

English

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature

scientific article published on 11 June 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

8 references

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

15 December 2019

18 December 2019

23 September 2020

0 references

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

acute myeloid leukemia

8 references

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

15 December 2019

18 December 2019

23 September 2020

cell surface receptor

1 reference

31 July 2019

proto-oncogene protein

1 reference

2 August 2019

1 reference

28 September 2019

membrane protein

1 reference

15 December 2019

neoplasm protein

1 reference

18 December 2019

antineoplastic combined chemotherapy protocols

1 reference

23 September 2020

author name string

Denise Wolleschak

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Enrico Schalk

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Christian Krogel

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Tina M Schnoeder

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Helga Luehr

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kathleen Jentsch-Ullrich

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Thomas Fischer

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Florian H Heidel

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 June 2013

9 references

Europe PubMed Central

PMC publication ID

17 August 2017

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

15 December 2019

18 December 2019

23 September 2020

Journal of Hematology & Oncology

9 references

Europe PubMed Central

PMC publication ID

17 August 2017

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

15 December 2019

18 December 2019

23 September 2020

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

39

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

8 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

31 July 2019

Europe PubMed Central

2 August 2019

Europe PubMed Central

28 September 2019

Europe PubMed Central

15 December 2019

Europe PubMed Central

18 December 2019

Europe PubMed Central

23 September 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Structural and numerical variation of FLT3/ITD in pediatric AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Cytogenetics in acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

29 September 2017

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

4 September 2018

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

4 September 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

4 September 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3686641

4 September 2018

Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23759001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23759001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML

1 reference

https://pubmed.ncbi.nlm.nih.gov/23759001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23759001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23759001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-8722-6-39

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36940606&oldid=2199607930"